Genexine to Supply 10 Million Doses of COVID-19 Vaccine to Indonesia

[Image source=Yonhap News]

[Asia Economy Reporter Seo So-jeong] Genexine (CEO Sung Young-chul, Woo Jung-won) announced on the 27th that it has agreed to supply 10 million doses of the COVID-19 vaccine candidate 'GX-19N' to Indonesia's Kalbe Farma.

Kalbe Farma will purchase at least 10 million doses of the DNA vaccine from Genexine and sell it in Indonesia, paying a certain portion of the vaccine sales revenue to Genexine as royalties. Instead of an initial contract payment, Kalbe Farma will cover clinical trial costs, and the two companies are discussing additional purchases.

To this end, last month the two companies submitted an Investigational New Drug (IND) application for Phase 2/3 clinical trials to Indonesia's Food and Drug Authority (BPOM) and are awaiting approval. Genexine plans to produce the vaccine at its manufacturing facility in Korea before supplying it.

Genexine has formed a consortium with GenNBio, SL Vaxigen, Vinex, POSTECH, the International Vaccine Institute, and KAIST to develop a COVID-19 preventive vaccine, and on the 7th of this month completed the first vaccine administration for all 150 subjects in the Phase 2a clinical trial in Korea.

Woo Jung-won, CEO of Genexine, said, "Indonesia has trusted the excellence and safety of our vaccine and promised joint clinical trials and advance purchase," adding, "Through the successful development of GX-19N, we will do our best to supply a safer COVID-19 preventive vaccine not only to Indonesia but also to our people."

This content was produced with the assistance of AI translation services.